Thioridazine: alternative and potentially effective therapy of the XDRTB patient

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Pulmonary tuberculosis infections caused by multi-drug resistant Mycobacterium tuberculosis has progressed to extensively drug resistant status (XDR-TB). XDR-TB is very difficult to treat successfully and results in high mortality. Globally, XDR-TB is now a major threat, especially to India and countries that were once part of the Soviet Union.

There is a potential alternative to current ineffective therapy that is solidly supported by in vitro, ex vivo and in vivo studies. It has reported successful therapies in 10 out of 12 non-responsive XDR-TB patients. That therapy is thioridazine, and it is the purpose of this mini-review to provide the rationale for thioridazine therapy, especially for compassionate reasons, when all other therapies have failed, depicting on extremely poor prognosis.
Original languageEnglish
Pages (from-to)130-132
Number of pages3
JournalLetters In Drug Design & Discovery
Issue number2
Publication statusPublished - Feb 2011


  • Macrophage activation, MDR-TB
  • MDR-TB
  • Phenothiazines
  • Therapy
  • Thioridazine
  • XDR-TB
  • Pulmonary tuberculosis infections
  • Mycobacterium tuberculosis
  • Thioridazine therapy
  • Mycobacteria bind
  • Pneumocyte II
  • Isoniazid
  • Rifampicin
  • Kanamycin
  • Amikacin
  • Capreomycin
  • Psychosis
  • Syphilis
  • Narcotize
  • Colorless neuroleptic chlorpromazine
  • Neuroleptic thioridazine


Dive into the research topics of 'Thioridazine: alternative and potentially effective therapy of the XDRTB patient'. Together they form a unique fingerprint.

Cite this